( HOUSTON--(BUSINESS WIRE)--Jun 7 2007 -...)ApoCell's Cancer Predictive Index Helps Oncologists Select the Most,Effective Targeted Drug Therapy,Health

HOUSTON--(BUSINESS WIRE)--Jun 7, 2007 - ApoCell, Inc. presented the results of a study conducted by researchers at the University of Chicago and ApoCell at the 2007 annual meeting of the American Society of Clinical Oncology (ASCO) held in Chicago in early June. The study showed that ApoCell's advanced pharmacodynamic biomarker assay technology provides reliable predictive data of clinical response. This study showed the benefit of treating aggressive head and neck cancer patients with a combination of targeted molecular drugs.

Cancer treatment is evolving from the use of highly toxic systemic compounds to targeted molecular drugs that are safer and faster acting because they aim only at cancer cell structures and their bio-mechanisms. Pharmacodynamics is an evolving field that encompasses the study of the biochemical and physiological effects of drugs, the mechanisms of drug action and the relationship between drug concentration and biological effect.

ApoCell has developed an analytical tool, the PDx Index(TM) (Pharmaco-Diagnostic Index), which indicates the likelihood of whether a targeted therapy will elicit a clinical response. The predictive index in this study was derived by comparing the biochemical state of a cancer cell receptor that is critical to the process of angiogenesis or vascularization of tumors. This PDx Index(TM) of patients with head and neck cancer showed a direct correlation between the drug regimen and patient response. This new technology is applicable to predicting the clinical outcome of most molecular targeted cancer drugs.

Dr. Darren Davis, ApoCell's President and CEO comments, "We have developed the PDx Index(TM) methodology to give drug developers, clinical investigators and oncologists a quantitative tool to predict effectiveness of cancer drug treatment. Recent research has demonstrated that different individuals respond differently to the same cancer drug therapy.
'"/>

Page: 1 2
Related medicine technology :

1. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Protox Announces Positive Clinical Data from Prostate Cancer Study
6. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
7. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
8. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
9. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
10. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
11. Rosetta Genomics and Weizmann Institute Scientists Identify Role of microRNA in Cancer Suppression